Ganoderma lucidum Spore Induced CA72-4 Elevation in Gastrointestinal Cancer

Integrative Cancer Therapies - Tập 13 Số 2 - Trang 161-166 - 2014
Bing Yan1, Xianze Meng1, Jun Shi1, Zhifeng Qin1, Pei‐Kuen Wei1, Lixing Lao2
1Second Military Medical University, Shanghai, China
2University of Maryland, Baltimore, MD USA

Tóm tắt

Ganoderma lucidum spore (GLS), an over-the-counter herbal supplement, is widely used by cancer patients in China. Although preclinical studies have shown it to be safe, complete safety data on GLS is still lacking. In this article, we report 5 cases of gastrointestinal cancer that were treated with GLS plus multiple strategies between 2010 and 2011. These patients presented with increased levels of the serum tumor marker CA72-4, one of the most valuable markers for monitoring therapeutic response in patients receiving gastrointestinal cancer treatment, after oral ingestion of GLS twice a day for 1 or 2 months. Interestingly, CA72-4 rapidly returned to normal levels when the patients discontinued the supplement and no change in clinical symptoms accompanied the CA72-4 surge. Taking into consideration that the underlying mechanism of this reaction is obscure, we suggest that additional studies are urgently needed and GLS be used with caution in cancer patients.

Từ khóa


Tài liệu tham khảo

10.1200/JCO.2000.18.13.2505

10.1093/annonc/mdi110

10.1038/ncprheum0406

10.1111/j.1749-6632.1999.tb08734.x

10.1007/BF01740932

Slivova V, 2004, J Cancer Integr Med, 2, 25

10.1248/cpb.50.837

10.1517/13543784.17.9.1353

10.1016/j.bbrc.2005.02.116

10.1002/ijc.10707

10.2174/1389557043403323

10.1016/j.canlet.2004.06.022

10.1016/S0304-3835(02)00080-0

10.1089/107555303322284776

Qi YF, 1999, Chin J Integr Traditional West Med, 19, 554

Cai S, 2010, Guide China Med, 8, 177

Kodama I, 1995, Int Surg, 80, 45

10.1016/S0002-9610(00)00549-3

10.1002/cncr.24602

10.1016/j.cct.2005.07.002

10.1186/1471-2407-11-183

10.1155/2013/268468

Li MQ, 2001, J Intervent Radiol, 10, 228

10.1016/j.tips.2005.09.006

10.1016/S0165-6147(02)02051-5

10.1016/j.enzmictec.2005.10.051

10.1016/j.leukres.2005.12.015

10.1016/j.enzmictec.2005.10.034

10.3736/jcim20040620

Guadagni F, 1992, Cancer Res, 52, 1222

Ikeguchi M, 1997, Hepatogastroenterology, 44, 866

10.1155/2000/595492

10.1007/s12325-008-0100-4

10.1177/172460089501000206

10.1080/02841860410032380

10.1200/JCO.1986.4.1.46

10.1182/asheducation-2009.1.313

10.1248/cpb.48.1026

10.1016/j.lfs.2006.09.001

10.1211/jpp.62.01.0016

10.1136/bmj.333.7564.391

Thông tin
Thông tin xuất bản

Integrative Cancer Therapies

Tập 13 Số 2

161-166

Thông tin tác giả